Y.D. More Investments Ltd Cuts Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Y.D. More Investments Ltd reduced its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,254,591 shares of the company's stock after selling 126,959 shares during the quarter. Takeda Pharmaceutical makes up 3.6% of Y.D. More Investments Ltd's portfolio, making the stock its 6th biggest position. Y.D. More Investments Ltd's holdings in Takeda Pharmaceutical were worth $17,903,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. XY Capital Ltd lifted its position in Takeda Pharmaceutical by 432.5% in the 4th quarter. XY Capital Ltd now owns 765,137 shares of the company's stock valued at $10,919,000 after purchasing an additional 621,440 shares during the last quarter. QRG Capital Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $5,511,000. Van ECK Associates Corp grew its stake in shares of Takeda Pharmaceutical by 21.6% in the 3rd quarter. Van ECK Associates Corp now owns 1,278,300 shares of the company's stock worth $19,775,000 after purchasing an additional 226,754 shares during the last quarter. HAP Trading LLC grew its stake in shares of Takeda Pharmaceutical by 543.4% in the 3rd quarter. HAP Trading LLC now owns 263,679 shares of the company's stock worth $4,079,000 after purchasing an additional 222,700 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $2,105,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Price Performance

Shares of TAK traded up $0.11 during mid-day trading on Wednesday, hitting $13.19. The company's stock had a trading volume of 1,293,554 shares, compared to its average volume of 1,799,791. The firm has a 50-day moving average price of $13.96 and a 200 day moving average price of $14.15. The stock has a market capitalization of $41.74 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 3.00 and a beta of 0.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55. Takeda Pharmaceutical Company Limited has a fifty-two week low of $13.01 and a fifty-two week high of $17.11.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The company had revenue of $7.52 billion during the quarter. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.